Sera Prognostics (SERA) Cash from Investing Activities (2020 - 2026)
Sera Prognostics (SERA) posted Cash from Investing Activities of $9.0 million for Q1 2026, up 52.55% on a QoQ basis from $5.9 million in Q4 2025, and up 120.05% year-over-year from $4.1 million in Q1 2025.
Sera Prognostics (SERA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Sera Prognostics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $9.0 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 120.05% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.3 million (up 192.38% YoY) and the FY2025 annual result came in at -$28.5 million, down 342.71% from the prior year.
- Cash from Investing Activities was $9.0 million for Q1 2026 at Sera Prognostics, up from $5.9 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.6 million in Q1 2022 and bottomed at -$44.8 million in Q1 2025.
- A 5-year average of -$105000.0 and a median of $4.9 million in 2024 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 35792.68% in 2022, while the deepest fall reached 1322.35% in 2022.
- Sera Prognostics' Cash from Investing Activities stood at -$1.6 million in 2022, then soared by 123.7% to $374000.0 in 2023, then surged by 1874.6% to $7.4 million in 2024, then slipped by 20.24% to $5.9 million in 2025, then surged by 52.55% to $9.0 million in 2026.
- Business Quant data shows SERA's Cash from Investing Activities at $9.0 million in Q1 2026, $5.9 million in Q4 2025, and $5.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.00 Bn | 175.71 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.69 Bn | 125.81 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.39 Bn | 66.93 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 47.97 Bn | 44.30 Bn | 1.29 Bn | -92.80 Mn |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.00 Bn | 1.98 Bn | -2.50 Bn |
| 7 | Dexcom | 28.21 Bn | 27.09 Bn | 750.30 Mn | -298.50 Mn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Sera Prognostics | 102.28 Mn | 102.28 Mn | -28,000.00 | 8.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.99 Mn |
| Mar 31, 2026 | 8.99 Mn |
| Dec 31, 2025 | 5.89 Mn |
| Dec 31, 2025 | 5.89 Mn |
| Sep 30, 2025 | 5.17 Mn |
| Sep 30, 2025 | 5.17 Mn |
| Jun 30, 2025 | 5.24 Mn |
| Jun 30, 2025 | 5.24 Mn |
| Mar 31, 2025 | -44.80 Mn |
| Mar 31, 2025 | -44.80 Mn |
| Dec 31, 2024 | 7.39 Mn |
| Dec 31, 2024 | 7.39 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Jun 30, 2024 | 5.15 Mn |
| Jun 30, 2024 | 5.15 Mn |
| Mar 31, 2024 | -5.69 Mn |
| Mar 31, 2024 | -5.69 Mn |
| Dec 31, 2023 | 374,000.00 |
| Dec 31, 2023 | 374,000.00 |